Hengrui (600276.SS) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Hengrui, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track 600276.SS live on Mooboard →
This week4
- Oct 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A2102 for Injection · Phase 1 / Phase 2 · Advanced or Metastatic Non-small Cell Lung CancerNCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-9821 Inhalation Suspension · Phase 2 · COPDNCT07640451: A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A2102；Adebrelimab；Cisplatin · Phase 1 / Phase 2 · Advanced or Metastatic Esophageal CancerNCT06474468: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A2102 · Phase 2 · Non-small Cell Lung CancerNCT07229729: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
31–90 days12
- Oct 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR6390 · Phase 3 · Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast CancerNCT04842617: Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A1811 combined with Pyrotinib. · Phase 1 / Phase 2 · HER2-expressing Advanced Solid TumorsNCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-8427 · Phase 3 · Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)NCT06569056: A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutBupivacaine Liposome Injection · Phase 2 · Local Analgesia Via Nerve BlockNCT06529432: A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery. Primary completion 2026-11 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutLutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide · Phase 3 · Advanced Gastroenteropancreatic Neuroendocrine TumorNCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-7787 injection · Phase 1 / Phase 2 · Advanced Solid TumorsNCT06605222: A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-1819 Injection · Phase 3 · Seasonal Allergic RhinitisNCT07688772: A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-6209 Capsules · Phase 1 / Phase 2 · Breast CancerNCT06974929: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-3167 Injection · Phase 2 · Diabetes Mellitus, Type 2NCT07472725: A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-5041 tablets · Phase 1 / Phase 2 · Prostate CancerNCT06568094: A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 · Phase 1 / Phase 2 · Advanced Non-small Cell Lung CancerNCT05482568: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer. Primary completion 2026-12 (estimated); status RECRUITING.
- Dec 13, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR0302 tablets、Placebo · Phase 3 · Psoriatic ArthritisNCT04957550: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis. Primary completion 2026-12-13 (estimated); status ACTIVE_NOT_RECRUITING.
Later9
- Dec 30, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-1905 · Phase 2 · AsthmaNCT05593250: A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma. Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A1811 · Phase 2 · HER2 Expression / Amplification in Patients With Biliary Tract CancerNCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutFuzuloparib , Abiraterone acetate and Prednisone · Phase 3 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT04691804: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR-A1811 · Phase 3 · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutThe SHR-1139 injection · Phase 2 · PsoriasisNCT07719530: Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis. Primary completion 2026-12-31 (estimated); status RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-9190 · Phase 3 · Neuromuscular BlockadeNCT07746726: Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults. Primary completion 2026-12-31 (estimated); status RECRUITING.
- Feb 2027ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutFH-006 for Injection · Phase 1 / Phase 2 · Malignant Solid TumorNCT07136142: A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors. Primary completion 2027-02 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutHRS-4642 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT06520488: A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors. Primary completion 2027-03 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Hengrui(600276.SS)Phase 2/3 readoutSHR0302 Tablets · Phase 2 · Non-segmental VitiligoNCT07251595: A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo. Primary completion 2027-03 (estimated); status RECRUITING.
How Hengrui has moved — past-year price reactions
How binary is 600276.SS? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1.2%
0
33.3%
242
Largest single-day moves
- +8.8%2026-06-29no matched headline
- +6.9%2026-03-27no matched headline
- -6%2026-08-20no matched headline
- +5.9%2026-01-05no matched headline
- -5.1%2025-10-28no matched headline
- -5%2026-07-17no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Hengrui — active clinical pipeline
Hengrui's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
106 assets146 programsPh1 32Ph2 75Ph3 38· 1 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicCardiovascularInfectiousOther
SHR-A1811Oncology
Phase 3
Breast CancerHER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaHER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNon-Small Cell Lung Cancer With HER2- MutationsOvarian Cancer
SHR-1819 InjectionImmunology
SHR-1905 InjectionImmunology
SHR-A1904Oncology
Phase 1
Phase 2
SHR-A2102 for InjectionOncology
CamrelizumabOncology · PD-1
FH-006Oncology
Phase 2
Hetrombopag OlamineCardiovascular · TPO-R
HRS-8427Infectious
SHR-A1811 InjectionOncology
camrelizumab； famitinib malateOncology
Phase 3
Fuzuloparib , Abiraterone acetate and PrednisoneOncology
HetrombopagCardiovascular · TPO-R
HR-1703Immunology
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumabOncology
Phase 3
HRS-4357 injectionOncology
HRS-4642 + AGOncology
HRS-9190Other
Phase 3
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinateOncology
Lutetium (177Lu) Oxodotreotide Injection；long-acting OctreotideOncology
PyrotinibOncology · EGFR/HER2
Phase 3
Rezvilutamide TabletsOncology
SHR-1316、Paclitaxel (Albumin Bound)、CarboplatinOncology
Phase 3
SHR-1703Autoimmune
SHR-A1811 for InjectionOncology
SHR2554; Chidamide analog tabletsOther
SHR6390Oncology
TACE+Camrelizumab+Apatinib mesylateOncology
Phase 3
SHR-2173 InjectionAutoimmune
Phase 1
SHR-A2102Oncology
Phase 1
HRS-4642Oncology
SHR-7787 InjectionOncology
HRS-4508 tabletOncology
Phase 2
RSS0393 ointmentAutoimmune
SHR-1139 InjectionAutoimmune
SHR-1703 InjectionImmunology
Phase 2
Bupivacaine Liposome InjectionOther
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; CarboplatinOncology
Phase 2
FH-006 for InjectionOncology
Phase 2
HRS-1167 tabletsOncology
Phase 2
HRS-1738 InjectionOncology
HRS-4508+ CapecitabineOncology
Phase 2
HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabineOncology
HRS-5041 tabletsOncology
Phase 2
HRS-6209 CapsulesOncology
Phase 2
HRS-6209 in Combination with FulvestrantOncology
HRS-6213Oncology
Phase 2
HRS-6768Oncology
Phase 2
HRS-7172 + AG + SHR-1316Oncology
Phase 2
HRS-8364 TabletOncology
Phase 2
HRS-9231Other
HRS-9813 capsulesOther
Phase 2
HRS-9821 Inhalation SuspensionImmunology
Phase 2
HS-20093 for InjectionOncology
Phase 2
Linperlisib ； RituximabOther
RSS0343 TabellaImmunology
Phase 2
SHR-1139Autoimmune
Phase 2
SHR-1139 intravenous injection.Autoimmune
SHR-1501Other
Phase 2
SHR-1501, AdebrelimabOncology
SHR-1905Immunology
Phase 2
SHR-3045 InjectionAutoimmune
SHR-3167Metabolic
Phase 2
SHR-4394Oncology
Phase 2
SHR-4602Oncology
Phase 2
SHR-7367 InjectionOncology
Phase 2
SHR-9803Oncology
Phase 2
SHR-9839 for InjectionOncology
Phase 2
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316Oncology
SHR-A1811 combined with Pyrotinib.Oncology
SHR-A2102；Adebrelimab；CisplatinOncology
SHR0302 TabletsAutoimmune
Phase 2
SHR0302Base gelAutoimmune
Phase 2
SHR2554 TabletsOncology
Phase 2
SHR2554; SHR-A2102Oncology
SHR4597Immunology
Phase 2
SHR4640 ；FebuxostatOther
The SHR-1139 injectionAutoimmune
Phase 2
Trastuzumab Rezetecan (SHR-A1811) injection; high doseOncology
Trastuzumab Rezetecan for InjectionOncology
[14C] HRS-9190Other
Phase 1
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tabletsOncology
HRS-1167Oncology
Phase 1
HRS-2329 TabletOncology
HRS-3005Oncology
Phase 1
HRS-3738Oncology
HRS-4508Oncology
Phase 1
HRS-5041Oncology
Phase 1
HRS-6093Oncology
HRS-6209Oncology
Phase 1
HRS-6209 Capsule (old formulation)Oncology
Phase 1
HRS-7085 tabletsAutoimmune
HRS-7172 TabletsOncology
HRS-7525 tabletsOncology
Phase 1
HRS-9821 Powder for InhalationImmunology
Phase 1
HRS8807Oncology
SHR-1049 InjectionOncology
Phase 1
SHR-2005Oncology
SHR-3836 administered as multiple doses.Oncology
Phase 1
SHR-4712 InjectionOncology
Phase 1
SHR-7590Autoimmune
SHR-9839Oncology
Phase 1
SHR-A1904; AdebrelimabOncology
SHR4394Oncology
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.